- Home
- TNXP vs AUDC Comparison
TNXP vs AUDC Comparison
Compare TNXP & AUDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- AUDC
- Stock Information
- Founded
- TNXP 2007
- AUDC 1992
- Country
- TNXP United States
- AUDC Israel
- Employees
- TNXP N/A
- AUDC N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- AUDC Telecommunications Equipment
- Sector
- TNXP Health Care
- AUDC Utilities
- Exchange
- TNXP Nasdaq
- AUDC Nasdaq
- Market Cap
- TNXP 335.6M
- AUDC 282.4M
- IPO Year
- TNXP N/A
- AUDC 1999
- Fundamental
- Price
- TNXP $22.41
- AUDC $9.76
- Analyst Decision
- TNXP Buy
- AUDC Buy
- Analyst Count
- TNXP 1
- AUDC 3
- Target Price
- TNXP $70.00
- AUDC $11.67
- AVG Volume (30 Days)
- TNXP 1.1M
- AUDC 105.4K
- Earning Date
- TNXP 11-11-2025
- AUDC 11-05-2025
- Dividend Yield
- TNXP N/A
- AUDC 4.10%
- EPS Growth
- TNXP N/A
- AUDC 3.22
- EPS
- TNXP N/A
- AUDC 0.46
- Revenue
- TNXP $9,831,000.00
- AUDC $243,249,000.00
- Revenue This Year
- TNXP $14.79
- AUDC $2.52
- Revenue Next Year
- TNXP $933.49
- AUDC $1.74
- P/E Ratio
- TNXP N/A
- AUDC $20.81
- Revenue Growth
- TNXP N/A
- AUDC N/A
- 52 Week Low
- TNXP $6.76
- AUDC $7.70
- 52 Week High
- TNXP $130.00
- AUDC $12.72
- Technical
- Relative Strength Index (RSI)
- TNXP 30.44
- AUDC 45.24
- Support Level
- TNXP $23.60
- AUDC $9.62
- Resistance Level
- TNXP $29.19
- AUDC $9.90
- Average True Range (ATR)
- TNXP 1.63
- AUDC 0.21
- MACD
- TNXP 0.12
- AUDC -0.04
- Stochastic Oscillator
- TNXP 5.31
- AUDC 19.50
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About AUDC AudioCodes Ltd.
AudioCodes Ltd develops and sells onverged voice over IP and data networking solutions, products and applications to service providers and channels, OEMs, network equipment providers and system integrators. Its products include IP phones, session border controllers, voice applications, multi-service business routers, digital and analog media gateways, among others. The company generates revenues from the sale of products through a direct sales force and sales representatives. Its geographic segments are Israel, Americas, Europe, and the Far East. It derives a majority of the revenues from Americas segment.